Holen Sie sich die Stockscreener-App
30.31
2.95%
-0.92
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$31.23
Offen:
$31.02
24-Stunden-Volumen:
1.39M
Relative Volume:
0.73
Marktkapitalisierung:
$2.92B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-4.6847
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
-4.75%
1M Leistung:
+7.83%
6M Leistung:
-24.77%
1J Leistung:
-47.59%
1-Tages-Spanne:
$30.27
$31.47
1-Wochen-Bereich:
$30.27
$31.87
52-Wochen-Spanne:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
30.31 | 3.02B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Alliancebernstein L.P. Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Reports Positive Phase 3 Gene Therapy Results - MSN
Ultragenyx Pharmaceutical Inc. $RARE Shares Purchased by Parkman Healthcare Partners LLC - MarketBeat
Ultragenyx Makes Bid for Dimension TherapeuticsBiotech Movers - TheStreet
Ultragenyx Pharmaceutical's (RARE) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Fred Alger Management LLC - MarketBeat
121,510 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Cubist Systematic Strategies LLC - MarketBeat
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome - Zacks Investment Research
Ultragenyx releases long-term phase 3 data on gene therapy for metabolic disorder - MSN
Alyeska Investment Group L.P. Has $54.15 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Cinctive Capital Management LP Purchases 14,301 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 04 - MarketScreener
Ionis Rare Neurological Disease Candidate Receives FDA Breakthrough StatusIonis Pharmaceuticals (NASDAQ:IONS) - Benzinga
RARE Reports Positive Long-Term Data From Metabolic Disorder Study - sharewise.com
Ultragenyx stock maintains Buy rating at H.C. Wainwright on strong GSD1a data By Investing.com - Investing.com South Africa
Ultragenyx stock maintains Buy rating at H.C. Wainwright on strong GSD1a data - Investing.com
Ultragenyx reports positive long-term data for GSDIa gene therapy - Investing.com
Cutter Capital Management LP Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports positive long-term data for GSDIa gene therapy By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Reports Positive Phase 3 Data on Rare Metabolic Disorder Treatment - MarketScreener
Ultragenyx Pharmaceutical Inc. Reports Positive Phase 3 Results for DTX401 Gene Therapy in Glycogen Storage Disease Type Ia with Significant Reductions in Cornstarch Intake and Improved Glycemic Control - Quiver Quantitative
Ultragenyx Announces Positive Longer-term Data from Phase 3 - GlobeNewswire
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - Yahoo Finance
Ultragenyx SVP Huizenga sells $2.6k in shares - Investing.com
Will Ultragenyx Pharmaceutical Inc. Bounce From 52 Week LowJuly 2025 Drop Watch & Safe Capital Growth Stock Tips - beatles.ru
Ultragenyx Pharmaceutical Inc. Volume Confirms Breakout — Analysts Bullish2025 Bull vs Bear & Free AI Powered Buy and Sell Recommendations - beatles.ru
Adage Capital Partners GP L.L.C. Has $77.82 Million Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
5 Companies Caught on a Carousel of FDA Confusion - BioSpace
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 6.5%Time to Buy? - MarketBeat
Real time scanner hits for Ultragenyx Pharmaceutical Inc. explained2025 Top Gainers & Consistent Profit Alerts - Newser
Ultragenyx Pharmaceutical Inc. stock daily chart insightsShort Setup & Daily Risk Controlled Trade Plans - Newser
Vestal Point Capital LP Cuts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Institutional scanner results for Ultragenyx Pharmaceutical Inc.Market Sentiment Report & Entry Point Confirmation Alerts - Newser
Graham Capital Management L.P. Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
How to use Fibonacci retracement on Ultragenyx Pharmaceutical Inc.Weekly Trend Report & Fast Gain Stock Tips - Newser
Live market analysis of Ultragenyx Pharmaceutical Inc.Portfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
What machine learning models say about Ultragenyx Pharmaceutical Inc.July 2025 Market Mood & Verified Technical Trade Signals - Newser
B. Metzler seel. Sohn & Co. AG Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
What earnings revisions data tells us about Ultragenyx Pharmaceutical Inc.2025 Institutional Moves & AI Powered Market Trend Analysis - Newser
Is Ultragenyx Pharmaceutical Inc. stock a good pick for beginnersGap Up & Long-Term Growth Plans - خودرو بانک
Ultragenyx Pharmaceutical Inc. recovery potential after sell offWeekly Investment Report & Safe Entry Point Identification - Newser
Applying sector rotation models to Ultragenyx Pharmaceutical Inc.July 2025 Selloffs & Safe Capital Growth Tips - Newser
Real time pattern detection on Ultragenyx Pharmaceutical Inc. stock2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Rare Disease Therapy Approvals By FDA Speed Up Via New ProcessNeurogene (NASDAQ:NGNE) - Benzinga
Ultragenyx’s Strategic Momentum: A Rare Disease Biotech on the Cusp of Multiple Catalysts - AInvest
Ultragenyx's Strategic Momentum in Rare Disease Innovation and Commercialization - AInvest
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 10 - MarketScreener
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Weekly Risk Report & Entry Point Confirmation Signals - Newser
Long term hold vs stop loss in Ultragenyx Pharmaceutical Inc.Global Markets & Low Risk High Reward Trade Ideas - Newser
Driehaus Capital Management LLC Has $30.88 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):